

## New risk assessment tool may better predict dynamic risk of heart disease

## November 7 2016

A new assessment tool—the Million Hearts Model Longitudinal ASCVD Risk Assessment tool—funded by the Centers for Medicare & Medicaid Services (CMS) in partnership with the American College of Cardiology and the American Heart Association— is designed to help predict the 10-year risk of developing atherosclerotic cardiovascular disease (ASVCD) and how that risk may change over time as preventive treatments are initiated. The tool is an extension of the ASCVD Pooled Cohort Equation first published in the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.

ASCVD is a group of conditions caused by atherosclerosis—a build-up of plaque that can harden and narrow the arteries and lead to heart attack, stroke or death. It is the leading cause of death, a major cause of disability, and a major source of healthcare costs. ASCVD is largely preventable through lifestyle changes and effective therapies.

The Million Hearts Initiative, developed by the United States
Department of Health and Human Services (HHS) and supported by the
ACC and AHA, aims to prevent 1 million heart attacks and strokes by
2017 through the management of the "ABCS"—aspirin therapy, blood
pressure control, cholesterol management and smoking cessation. In
support of the Million Hearts Initiative, the Center for Medicare and
Medicaid Innovation (Innovation Center), a part of CMS, is testing a
large-cluster randomized payment model test of value-based
payment—the Million Hearts Cardiovascular Disease (CVD) Risk
Reduction Model—to determine whether financially rewarding



clinicians for reducing 10-year predicted risk for ASCVD across their patient population is an effective way to reduce first-time heart attacks and strokes. Over 500 applicant organizations were selected to participate in the Million Hearts Model. In order to help test this Model, CMS funded the development of the Million Hearts Longitudinal ASCVD Risk Assessment tool, in partnership with the ACC and AHA, to improve on the ACC/AHA Pooled Cohort Equations risk estimator, currently used by the practices participating in the Model. In the study, the tool aims to provide a framework for delivering appropriate risk-reducing strategies to Medicare patients with a 10-year ASCVD risk >30 percent.

To create the new tool, the Innovation Center's Million Hearts CVD Risk Reduction Model partnered with the chairs of the writing committee for the 2013 guideline, David C. Goff, Jr. MD, PhD, FAHA and Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA. The tool is not a replacement for the ACC/AHA Pooled Cohort Equations risk estimator. Rather, the risk estimator is incorporated into the initial risk assessments of patients in the Model. The committee added existing evidence to extend the risk equation.

"The new tool is based upon a formal systematic review of the evidence of ABCS therapies to define what the expected risk reduction would be from each one, used alone or in combination," said Lloyd-Jones, who is the chair of the writing committee that describes the new tool. "At an initial visit, clinicians can use the tool to project the expected updated risk if one or more of the ABCS interventions were initiated, then it can be used at a subsequent follow-up visit to estimate what is the actual achieved updated risk based on the patient's individual response to those therapies and any lifestyle changes they may have made as well."

This approach to personalized estimation of benefits from risk-reducing therapies may represent the next wave in clinical practice to help target



therapies to those in whom they will provide the greatest benefit.

The goal of the tool is to assist not only clinicians, but also patients, in understanding risk, monitoring risk over time, and quantifying potential benefits of preventive therapies.

"This tool will help clinicians and patients with shared-decision making and will aid in the understanding of how the ABCS may help to reduce risk," said Lloyd-Jones.

**More information:** Donald M. Lloyd-Jones et al. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool, *Circulation* (2016). DOI: 10.1161/CIR.00000000000000467

David C. Goff et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, *Circulation* (2014). DOI: 10.1161/01.cir.0000437741.48606.98

## Provided by American Heart Association

Citation: New risk assessment tool may better predict dynamic risk of heart disease (2016, November 7) retrieved 5 May 2024 from <a href="https://medicalxpress.com/news/2016-11-tool-dynamic-heart-disease.html">https://medicalxpress.com/news/2016-11-tool-dynamic-heart-disease.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.